We all keep hearing about the major, major risks o
Post# of 72440
(Total Views: 365)
Posted On: 12/12/2018 2:49:37 PM
We all keep hearing about the major, major risks of investing in biotech startups due to the large, large percentage of failures thru the clinical trial process.
I am smart enough to know those risks are real - but I also strongly believe that the risks are weighted far, far heavier to the safety of the drugs as opposed to the efficacy of the drugs being tested.
This is why I have invested more and more into IPIX as time has progressed, the safety profiles keep showing that all 3 drugs are nearly rock solid.
Kevetrin - What else needs to be said other than they shut down the P1 trial after 3 years and increasing the dosage from 10 to 800 units during that time, all the while dealing ONLY with P4 cancer patients, the weakest population of patients one could find, because they couldn't get any of them to reach the bad terminal conditions stated at the start of the trial. Add to that the drug was found to have no systemic buildup and it clears the body so fast that it can only be effectively delivered via pill every so many hours. This is a success story just waiting on a pill formulation to come into place and I thought I had heard IPIX was over 1/2 way done in bringing the pill to completion.
Prurisol - Have heard NO safety issues to date other than some minor issues that they couldn't even trace to whether it was due to P or not. They also have the original drug from which P is a salt having decades of exceedingly strong safety data. Ergo, pretty damn safe and I believe the P2b data will show we have a monster winner on our hands. As to the other indications for dermatology and auto-immune issues that should be a lock for safety since derm will be via a topical cream (very safe) and AI indications still have the same safe drug being taken orally.
Brilacidin - Too strong a dose caused some blood pressure issues but when tweaked and dosage weakened have heard no further bad side effects. B is strong, no doubt about it, and IPIX will have to be sure it doesn't harm any good bacteria in the gut but they have the brains to get around possible problems in this area.
Overall, safety is maybe our greatest strength and thus our greatest friend for the success, massive success, of IPIX.
That only leaves efficacy and to date all 3 have shined in trials to date.
Share price is scary, getting the first partner seems scary, but when looking closely at what we own how can one say anything other than that the evidence to date shows an extremely high propensity for success?
Have bought more today, last purchase without a doubt as more than fully loaded, and feeling confident I have sided with a major winner.
I am smart enough to know those risks are real - but I also strongly believe that the risks are weighted far, far heavier to the safety of the drugs as opposed to the efficacy of the drugs being tested.
This is why I have invested more and more into IPIX as time has progressed, the safety profiles keep showing that all 3 drugs are nearly rock solid.
Kevetrin - What else needs to be said other than they shut down the P1 trial after 3 years and increasing the dosage from 10 to 800 units during that time, all the while dealing ONLY with P4 cancer patients, the weakest population of patients one could find, because they couldn't get any of them to reach the bad terminal conditions stated at the start of the trial. Add to that the drug was found to have no systemic buildup and it clears the body so fast that it can only be effectively delivered via pill every so many hours. This is a success story just waiting on a pill formulation to come into place and I thought I had heard IPIX was over 1/2 way done in bringing the pill to completion.
Prurisol - Have heard NO safety issues to date other than some minor issues that they couldn't even trace to whether it was due to P or not. They also have the original drug from which P is a salt having decades of exceedingly strong safety data. Ergo, pretty damn safe and I believe the P2b data will show we have a monster winner on our hands. As to the other indications for dermatology and auto-immune issues that should be a lock for safety since derm will be via a topical cream (very safe) and AI indications still have the same safe drug being taken orally.
Brilacidin - Too strong a dose caused some blood pressure issues but when tweaked and dosage weakened have heard no further bad side effects. B is strong, no doubt about it, and IPIX will have to be sure it doesn't harm any good bacteria in the gut but they have the brains to get around possible problems in this area.
Overall, safety is maybe our greatest strength and thus our greatest friend for the success, massive success, of IPIX.
That only leaves efficacy and to date all 3 have shined in trials to date.
Share price is scary, getting the first partner seems scary, but when looking closely at what we own how can one say anything other than that the evidence to date shows an extremely high propensity for success?
Have bought more today, last purchase without a doubt as more than fully loaded, and feeling confident I have sided with a major winner.
(9)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼